Audit: QRS - Betaine for Health & Longevity
Audit conducted on 11/09/2026 06:46 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol values (ER 306/316/320), time-to-effect (ER 356), benefits/risks headings (ER 142-242), gates (ER 260-286), monitoring table (ER 384-391), qualitative markers (ER 395-401). All literally supported. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing carried over: “No circadian dependence demonstrated” (ER 316), “pairing untested” (ER 274), “No established target” for TMAO (ER 391). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindication thresholds preserved unchanged (methionine >1,000 umol/L; LDL >160 mg/dL; 4 g daily or more). Pregnancy and lactation carried as an avoid item, not softened. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications. No Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, NCT identifiers, author names, or brand names anywhere in the QRS; the only URL is the template’s AI4L link (line 424). |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, trade-off-forward register. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven while remaining readable; tiers and targets give the reader something to act on. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents findings and ranges; issues no directives. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring cadence is stated descriptively (“lipid recheck at 6 to 8 weeks”), not as an instruction to the reader. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise”, or “should” in the document’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language throughout; technical terms appear only where they are the decision gate itself (e.g. cystathionine beta-synthase deficiency, trimethylaminuria). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, benefit, and risk item is a single condensed clause. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a proactive reader weighing the homocysteine benefit against the lipid cost. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents a monitoring panel of eight markers and a multi-visit cadence without hedging on the effort involved. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not pitched at the general population. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The lipid trade-off is surfaced in the lede, the Risks card, the contraindications and the monitoring table — the weighting a risk-aware reader needs. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”; the sheet uses “longevity” (title, at-a-glance). |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | No colloquial or consumer-grade terms. “harmful cholesterol” in the at-a-glance is the ER Conclusion’s own wording (ER 419) and is required there by 7.4, which bars the acronym LDL. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings present and unmodified: Protocol (446), Time to effect (490), Benefits (537), Risk & Side Effects (615), Monitoring (640), Qualitative Assessment (768), Contraindications (563), Key Interactions (580), tier labels High/Medium/Low/Speculative, and Marker/Target/Why (644-646). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template spans present; marker_#* and qualitative_item# are expanded to 8 and 4 concrete rows respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Structural diff against [qrs_template] shows only span-content substitutions — no markup, CSS, footer, or comment outside a span was altered. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section feeding the QRS is empty, so no empty-state phrasing is required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | ER bold labels reused verbatim: “Standard supplemental dose”, “Split versus single dose”, “Best time of day” (ER 306/320/316); “Training performance”, “Digestive tolerance”, “Body odor”, “Energy and recovery” (ER 395-401); all nine interaction labels (ER 260-276). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels. Time-to-effect labels (“Strength”, “Homocysteine”, “Lipid increase”) are the ER’s own terms from the Time to effect bullet (ER 356). Interaction parentheticals are trimmed only as 9.4/9.5 require. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No tier emoji in the file; tiers are carried by bold labels and CSS palette. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed rather than extended: gate and tier items are single clauses, the at-a-glance is at its 60-word budget, and the Monitoring table carries only the ER’s own eight rows with shortened Why text. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | HTML comment opens at line 2, immediately after <!doctype html>, before head and body. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML delimited by — at lines 3 and 13; the preceding title text is outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Inside an HTML comment; not echoed by any visible element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed. Only duration is quoted, and “00:02” contains a colon, which YAML requires be quoted. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: betaine_2026-0911-0304_Opus_ER.md — matches the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02 — matches the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0911-0614 — correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | Single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | Nickname plus version number, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: betaine_2026-0911-0304_Opus_QRS.html — matches the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Confirmed again against the full block: no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Betaine for Health & Longevity - Quick Reference Sheet” — canonical_topic entity-encoded plus the fixed suffix. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Betaine for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/11/2026 — qrs_creation_date 2026-0911-0614 in MM/DD/YYYY. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: Opus 5. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Subline carries only the template’s date, source-ER link, AI4L link and model. No AKA line, despite the ER carrying six alternate names. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion’s first two paragraphs (ER 419-421) into the methyl-donor job, the lipid consequence, the two narrow benefit signals, and the animal basis of the longevity claim. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words, within the 60-word ceiling. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: methyl groups and the cholesterol trade-off to ER 419; strength and liver fat to ER 421; aged mice to ER 421. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms. “methyl groups” is glossed as “small chemical tags”, homocysteine as “the blood marker”, and LDL is rendered as “harmful cholesterol”. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial names, years, or sample sizes. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect sizes or statistics; “consistently” is qualitative. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER’s “Populations who should avoid Betaine” list (ER 278-286) inside Key Interactions & Contraindications. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All four ER avoid-populations represented, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Four <li> elements inside the [stop_items] span (lines 566-575). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Trailing explanations stripped: the em-dash clause “— the setting in which brain swelling has occurred” (ER 280) and “in which any added trimethylamine load worsens symptoms” (ER 284) are gone. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and dose qualifiers preserved: methionine above 1,000 µmol/L, LDL above 160 mg/dL, 4 g daily or more, and the “(fish-odor syndrome from FMO3 deficiency)” parenthetical. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names four avoid-populations, so the section is correctly populated rather than left empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the ER’s nine interaction bullets (ER 260-276). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine interactions carried; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine <li> elements inside the [caution_items] span (lines 583-605). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Each item reduced to label plus the key consequence (“additive and intended”, “opposed in outcome”, “pairing untested”); severity ratings and mechanistic sentences dropped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs preserved in every case — atorvastatin, ezetimibe, methotrexate, trimethoprim, omeprazole, nicotinic acid, nicotinamide mononucleotide and riboside, folic acid, B12, B6 — with only the mechanistic gloss trimmed, as 9.4 requires and 9.5 permits. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names nine interactions, so the section is correctly populated. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | Derived from the ER Therapeutic Protocol section (ER 304-330). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, dose splitting, and timing — the three aspects a reader must settle before starting, and the three the ER treats as primary. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER names thirteen protocol aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields populated from ER 306, 320 and 316; values and subs match the ER’s figures (2–3 g daily, 1.25–3 g twice daily, no circadian dependence). |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Strength, homocysteine, and the lipid increase — the only three time-to-effect aspects the ER quantifies (ER 356). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered Strength (High-tier benefit) then Homocysteine (Low-tier benefit), with the lipid increase — which has no associated benefit — last. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields populated; the plateau note in time_2_sub is supported by ER 318. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Derived from the ER Expected Benefits section (ER 136-186). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans present and populated (lines 539-556). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier reduced to the ER’s own benefit headings; magnitudes, mechanisms and trial counts dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content carried; the ER’s ⚠️ Conflicted markers on liver fat, body fat and cognition are also dropped, as the tier already encodes evidence strength. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Derived from the ER Potential Risks & Side Effects section (ER 204-242). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans present and populated (lines 617-634). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier reduced to the ER’s own risk headings; the 35 percent GI rate, the TMAO figures and the case-report counts are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | The “(Brain Swelling)” parenthetical from the ER’s cerebral edema heading (ER 232) is stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four tiers carry items in the ER, so no span needs hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the ER Monitoring Protocol & Defining Success section (ER 376-391). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight ER biomarker rows present in order: homocysteine, LDL, total cholesterol and triglycerides, ALT, plasma methionine, eGFR, B12 and folate, TMAO. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Populated from ER 380: baseline panel, lipid recheck at 6 to 8 weeks, homocysteine at 12 weeks, then annual, returning to 8 weeks after a dose change. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Derived from the qualitative-marker list at the end of the ER Monitoring section (ER 393-401). |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All four present: training performance, digestive tolerance, body odor, energy and recovery. |
Issues 11/09/2026 06:46
Pass rate 100.00%. No issues found.
Issues 11/09/2026 06:39
- 1.2 — Circadian hedge dropped: [action_3_value] at line 480 reads “No circadian dependence”, while the ER (line 316) states “no circadian dependence has been demonstrated”; the QRS turns an absence of evidence into a positive negative claim.
Fixes 11/09/2026 06:39
- 1.2 — Circadian hedge restored: [action_3_value] changed from “No circadian dependence” to “No circadian dependence demonstrated”, matching the ER’s hedged phrasing “no circadian dependence has been demonstrated”.
Issues 11/09/2026 06:33
- 1.3 — Methionine monitoring condition dropped: marker_5_why (QRS line 709) reads “needed only above 6 g daily”, while the ER Monitoring table (ER line 388) states “Needed only above 6 g daily or in inherited metabolic disease”; dropping the second condition strengthens the exclusion and removes the inherited-disease case the ER flags.
Fixes 11/09/2026 06:33
- 1.3 — Methionine monitoring condition restored: marker_5_why now reads “Accumulation precedes brain swelling; needed only above 6 g daily or in inherited metabolic disease”, restoring the second condition from the ER Monitoring table.
Issues 11/09/2026 06:26
- 2.6 / 2.9 — Dangling possessor in TMAO target: [marker_8_target] at line 743 reads “track the change from own baseline”, whereas the ER writes “track the change from the individual’s own baseline”; the truncation leaves “own” without a possessor and reads as an implied second-person “your own baseline”.
Fixes 11/09/2026 06:26
- 2.6 / 2.9 — Dangling possessor in TMAO target: [marker_8_target] changed from “track the change from own baseline” to “track the change from the individual’s own baseline”, restoring the ER’s third-person phrasing and removing the implied second-person address.
Issues 11/09/2026 06:19
- 1.1 — Plateau misattributed to homocysteine:
time_2_sub(QRS line 516) states “plasma concentrations plateau after about a week” under the “Homocysteine” label, but the ER attributes that one-week plateau to betaine plasma concentrations (ER line 318), not to homocysteine.
Fixes 11/09/2026 06:19
- 1.1 — Plateau misattributed to homocysteine: Changed
time_2_subfrom “plasma concentrations plateau after about a week” to “betaine plasma concentrations plateau after about a week”, so the one-week plateau is attributed to betaine as in the ER rather than to homocysteine.